APL Nameplate
  • Volume/Page
  • Keyword
  • DOI
  • Citation
  • Advanced
   
 
 
 

Flickr Twitter iResearch App Facebook

BROWSE VOLUMES

Year Range: 
Search Issue | RSS Feeds RSS
Previous Issue Next Issue

31 Jan 2011

Volume 98, Issue 5, Articles (05xxxx)

Issue Cover Spotlight Figure

Appl. Phys. Lett. 98, 053101 (2011); http://dx.doi.org/10.1063/1.3549154 (3 pages)

Minggang Zeng, Lei Shen, Ming Yang, Chun Zhang, and Yuanping Feng
Enlarge Image | Read More
Return to All Sections
back to top
RSS Feeds

Measurement of relative biological effectiveness of protons in human cancer cells using a laser-driven quasimonoenergetic proton beamline

A. Yogo, T. Maeda, T. Hori, H. Sakaki, K. Ogura, M. Nishiuchi, A. Sagisaka, H. Kiriyama, H. Okada, S. Kanazawa, T. Shimomura, Y. Nakai, M. Tanoue, F. Sasao, P. R. Bolton, et al.

Appl. Phys. Lett. 98, 053701 (2011); http://dx.doi.org/10.1063/1.3551623 (3 pages) | Cited 9 times

Online Publication Date: 1 February 2011

Full Text: Read Online (HTML) | Download PDF

Show Abstract
Human cancer cells are irradiated by laser-driven quasimonoenergetic protons. Laser pulse intensities at the 5×1019 W/cm2 level provide the source and acceleration field for protons that are subsequently transported by four energy-selective dipole magnets. The transport line delivers 2.25 MeV protons with an energy spread of 0.66 MeV and a bunch duration of 20 ns. The survival fraction of in vitro cells from a human salivary gland tumor is measured with a colony formation assay following proton irradiation at dose levels of up to 8 Gy, for which the single bunch dose rate is 1×107 Gy/s and the effective dose rate is 0.2 Gy/s for 1 Hz repetition of irradiation. Relative biological effectiveness at the 10% survival fraction is measured to be 1.20±0.11 using protons with a linear energy transfer of 17.1 keV/μm.
Show PACS
87.55.dk Dose-volume analysis
87.17.-d Cell processes
87.19.xj Cancer

Charge transport in fibrous/not fibrous α3-helical and (5Q,7Q)α3 variant peptides

L. M. Bezerril, U. L. Fulco, J. I. N. Oliveira, G. Corso, E. L. Albuquerque, V. N. Freire, and E. W. S. Caetano

Appl. Phys. Lett. 98, 053702 (2011); http://dx.doi.org/10.1063/1.3551713 (3 pages) | Cited 2 times

Online Publication Date: 2 February 2011

Full Text: Read Online (HTML) | Download PDF

Show Abstract
Although differing only by the Ala→Gln substitution at the fifth or seventh position of the α3-peptide amino acid sequence (Leu-Glu-Thr-Leu-Ala-Lys-Ala)3, the 5Qα3 variant forms fibrous assemblies more attenuated than those of the α3-peptide, while the 7Qα3 variant does not form fibrils. A tight-binding transport modeling was performed to obtain their current-voltage patterns, with hopping energies of the dipeptides calculated within the density functional theory framework. Beyond the semiconductor character, we obtain that the current pattern can be used to distinguish them, suggesting that it can be useful for the development of devices as diagnostics tools for amyloidosislike diseases.
Show PACS
87.15.hj Transport dynamics
87.15.hp Conformational changes
87.14.ef Peptides

A multiscale model to evaluate the efficacy of anticancer therapies based on chimeric polypeptide nanoparticles

L. R. Paiva and M. L. Martins

Appl. Phys. Lett. 98, 053703 (2011); http://dx.doi.org/10.1063/1.3551619 (3 pages)

Online Publication Date: 3 February 2011

Full Text: Read Online (HTML) | Download PDF

Show Abstract
A multiscale model for tumor growth and its chemotherapy using conjugate nanoparticles is presented, and the corresponding therapeutic outcomes are evaluated. It is found that doxorubicin assembled into chimeric polypeptide nanoparticles cannot eradicate either vascularized primary tumors or avascular micrometastasis even administrated at loads close to their maximum tolerated doses. Furthermore, an effective and safety treatment demands for conjugate nanoparticles targeted to the malignant cells with much higher specificity and affinity than those currently observed in order to leave most of the normal tissues unaffected and to ensure a fast intracellular drug accumulation.
Show PACS
87.85.Rs Nanotechnologies-applications
87.17.-d Cell processes
87.85.J- Biomaterials
87.19.xj Cancer
Return to All Sections
Close

Google Calendar

ADVERTISEMENT

Go to AIP Home   © AIP Publishing LLC
close